Hypoxia Imaging With 18F FAZA. Prognostic Impact in Cervical Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2006 by Medical University of Vienna.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Medical University of Vienna
ClinicalTrials.gov Identifier:
NCT00388687
First received: October 16, 2006
Last updated: NA
Last verified: October 2006
History: No changes posted
  Purpose

The aim of this study is to visualize the tumor hypoxic tissue, the potential quantitative changes and the biological behavior of cervical carcinoma (primary and / or lymph nodes) before, during and after radiochemotherapy with the novel hypoxia PET tracer 18FAZA.


Condition Intervention Phase
Uterine Cervical Neoplasms
Drug: 18F Fluoroazomycin Arabinoside (FAZA)
Phase 2

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Official Title: Hypoxia Imaging With the Novel Radiopharmaceutical 18F Fluoroazomycin Arabinoside (FAZA)- Prognostic Impact in Cervical Cancer

Resource links provided by NLM:


Further study details as provided by Medical University of Vienna:

Estimated Enrollment: 25
Study Start Date: July 2006
Estimated Study Completion Date: July 2007
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • First diagnosis of histologically proven cervical cancer FIGO stage IB2 to IVA.
  • Treatment intention for the purpose of achieving cure
  • Age < 80 years
  • No previous standard or radical hysterectomy

Exclusion Criteria:

  • Pregnancy, breast-feeding women, patients that are not able to lie motionless for one hour.Palliative treatment, recurrent disease, neoadjuvant chemotherapy, other pre-existing malignancies, age > 80 years,
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00388687

Contacts
Contact: Matthias Schuetz, M.D. 00431404005550 matthias.schuetz@meduniwien.ac.at
Contact: Barbara Bachtiary, Prof. M.D 00431404007676 barbara.bachtiary@meduniwien.ac.at

Locations
Austria
Medical University of Vienna Recruiting
Vienna, Austria, 1090
Contact: Barbara Bachtiary, Prof. M.D.    00431404007676    barbara.bachtiary@meduniwien.ac.at   
Principal Investigator: Georgios Karanikas, Prof. M.D.         
Medical Universitiy of Vienna Recruiting
Vienna, Austria, 1090
Contact: Barbara Bachtiary, Prof. M.D.    00431404007676    barbara.bachtiary@meduniwien.ac.at   
Sponsors and Collaborators
Medical University of Vienna
Investigators
Study Director: Georgios Karanikas, Prof. M.D. Medical Universitiy of Vienna
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00388687     History of Changes
Other Study ID Numbers: EK Nr: 241/2006
Study First Received: October 16, 2006
Last Updated: October 16, 2006
Health Authority: Austria: Federal Ministry for Health and Women

Keywords provided by Medical University of Vienna:
Hypoxia
FAZA
PET
Radiochemotherapy

Additional relevant MeSH terms:
Uterine Cervical Neoplasms
Neoplasms
Anoxia
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female
Signs and Symptoms, Respiratory
Signs and Symptoms
Radiopharmaceuticals
Diagnostic Uses of Chemicals
Pharmacologic Actions
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 15, 2014